KR102213154B1 - 재조합 ｈｃｇ를 포함하는 약학 조제물 - Google Patents

재조합 ｈｃｇ를 포함하는 약학 조제물 Download PDF

Info

Publication number
KR102213154B1
KR102213154B1 KR1020197016021A KR20197016021A KR102213154B1 KR 102213154 B1 KR102213154 B1 KR 102213154B1 KR 1020197016021 A KR1020197016021 A KR 1020197016021A KR 20197016021 A KR20197016021 A KR 20197016021A KR 102213154 B1 KR102213154 B1 KR 102213154B1
Authority
KR
South Korea
Prior art keywords
hcg
rhcg
mol
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016021A
Other languages
English (en)
Korean (ko)
Other versions
KR20190067256A (ko
Inventor
이안 코팅햄
다니엘 플락신
리차드 보이드 화이트
Original Assignee
훼링 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훼링 비.브이. filed Critical 훼링 비.브이.
Publication of KR20190067256A publication Critical patent/KR20190067256A/ko
Application granted granted Critical
Publication of KR102213154B1 publication Critical patent/KR102213154B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197016021A 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물 Active KR102213154B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
EP09252360.4 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197007226A Division KR101987982B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003233A Division KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Publications (2)

Publication Number Publication Date
KR20190067256A KR20190067256A (ko) 2019-06-14
KR102213154B1 true KR102213154B1 (ko) 2021-02-05

Family

ID=41471027

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020197016021A Active KR102213154B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020177034392A Withdrawn KR20170133531A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020127008827A Active KR101804479B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020217037028A Active KR102489143B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020237001308A Pending KR20230012104A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020197007226A Active KR101987982B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020217003233A Ceased KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020177034392A Withdrawn KR20170133531A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020127008827A Active KR101804479B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020217037028A Active KR102489143B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020237001308A Pending KR20230012104A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020197007226A Active KR101987982B1 (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물
KR1020217003233A Ceased KR20210014767A (ko) 2009-10-05 2010-10-04 재조합 ｈｃｇ를 포함하는 약학 조제물

Country Status (25)

Country Link
US (5) US8975226B2 (enExample)
EP (2) EP2486051B1 (enExample)
JP (6) JP6176924B2 (enExample)
KR (7) KR102213154B1 (enExample)
CN (1) CN107050434B (enExample)
AR (2) AR079876A1 (enExample)
AU (1) AU2010304922B2 (enExample)
BR (1) BR112012007990A2 (enExample)
CA (1) CA2776790A1 (enExample)
DK (1) DK2486051T3 (enExample)
ES (2) ES3036152T3 (enExample)
HR (1) HRP20200941T1 (enExample)
HU (1) HUE050793T2 (enExample)
IL (3) IL218548A (enExample)
IN (1) IN2012DN02073A (enExample)
JO (1) JOP20200039A1 (enExample)
LT (1) LT2486051T (enExample)
MX (1) MX2012003951A (enExample)
PL (1) PL2486051T3 (enExample)
PT (1) PT2486051T (enExample)
RS (1) RS60413B1 (enExample)
RU (2) RU2724528C2 (enExample)
SI (1) SI2486051T1 (enExample)
TW (2) TWI532495B (enExample)
WO (1) WO2011042688A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US10144923B2 (en) 2012-12-10 2018-12-04 Seikagaku Corporation Recombinant Factor C and method for producing the same, and method for measuring endotoxin
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
SG11201706832PA (en) * 2015-04-24 2017-09-28 Ferring Bv Method of production of gonadotrophin
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
JP2021522268A (ja) 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ 制御された卵巣刺激のための組成物
CR20220367A (es) * 2020-02-05 2022-08-30 Novartis Ag Célula cho que expresa heterodímeros il-15
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226681A1 (en) * 2004-02-13 2008-09-18 Glycotope Gmbh Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
AU707796B2 (en) * 1995-03-21 1999-07-22 Merck Serono Sa HCG liquid formulations
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
CN100404551C (zh) 1997-06-25 2008-07-23 雪兰诺实验室有限公司 二硫键交联的糖蛋白激素类似物及其制备和应用
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
US7297777B2 (en) * 2000-02-22 2007-11-20 Laboratoires Serono Sa Process of purification of hCG and recombinant hCG purified by that method
WO2003022302A2 (en) 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
JP2005515974A (ja) 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
EA008220B1 (ru) * 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP1615945B1 (en) * 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
SI1654353T1 (sl) * 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
ATE476666T1 (de) * 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
WO2007022206A1 (en) * 2005-08-15 2007-02-22 Siemens Vdo Automotive Corporation Automotive diesel exhaust hc dosing valve
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US9187532B2 (en) * 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) * 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103619358B (zh) * 2011-03-31 2017-02-15 辉凌公司 药物制剂
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226681A1 (en) * 2004-02-13 2008-09-18 Glycotope Gmbh Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production

Also Published As

Publication number Publication date
SI2486051T1 (sl) 2020-08-31
EP2486051A1 (en) 2012-08-15
US20180030107A1 (en) 2018-02-01
KR102489143B1 (ko) 2023-01-13
EP3611185B1 (en) 2025-04-30
MX2012003951A (es) 2012-05-29
JP2016074680A (ja) 2016-05-12
US10526390B2 (en) 2020-01-07
US20200247863A1 (en) 2020-08-06
CN102549011A (zh) 2012-07-04
RU2724528C2 (ru) 2020-06-23
JP2023075144A (ja) 2023-05-30
AR079876A1 (es) 2012-02-29
JP6176924B2 (ja) 2017-08-09
JP2018076296A (ja) 2018-05-17
IL218548A0 (en) 2012-05-31
KR20210141771A (ko) 2021-11-23
RU2012112907A (ru) 2013-11-10
KR20190028823A (ko) 2019-03-19
ES2798258T3 (es) 2020-12-10
PL2486051T3 (pl) 2020-09-07
US9676835B2 (en) 2017-06-13
US12234272B2 (en) 2025-02-25
IL250733B (en) 2019-07-31
KR101804479B1 (ko) 2017-12-05
HRP20200941T1 (hr) 2020-09-18
HUE050793T2 (hu) 2021-01-28
RS60413B1 (sr) 2020-07-31
PT2486051T (pt) 2020-06-17
TW201113030A (en) 2011-04-16
JP2020000246A (ja) 2020-01-09
KR101987982B1 (ko) 2019-06-11
RU2016118236A3 (enExample) 2019-09-18
KR20170133531A (ko) 2017-12-05
US8975226B2 (en) 2015-03-10
IL267556A (en) 2019-08-29
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
US20220340634A1 (en) 2022-10-27
JP7196244B2 (ja) 2022-12-26
AR125991A2 (es) 2023-08-30
JP2013506708A (ja) 2013-02-28
EP2486051B1 (en) 2020-03-25
KR20230012104A (ko) 2023-01-25
TW201632198A (zh) 2016-09-16
KR20210014767A (ko) 2021-02-09
CN107050434B (zh) 2021-07-27
DK2486051T3 (da) 2020-06-22
CN107050434A (zh) 2017-08-18
US20140249082A1 (en) 2014-09-04
TWI532495B (zh) 2016-05-11
RU2016118236A (ru) 2018-10-29
US20130023476A1 (en) 2013-01-24
BR112012007990A2 (pt) 2017-07-25
LT2486051T (lt) 2020-07-10
JP2021176867A (ja) 2021-11-11
WO2011042688A1 (en) 2011-04-14
JP6580104B2 (ja) 2019-09-25
ES3036152T3 (en) 2025-09-15
AU2010304922B2 (en) 2014-11-06
IL218548A (en) 2017-03-30
IL250733A0 (en) 2017-04-30
JOP20200039A1 (ar) 2022-10-30
US11292824B2 (en) 2022-04-05
KR20190067256A (ko) 2019-06-14
JP7292153B2 (ja) 2023-06-16
IN2012DN02073A (enExample) 2015-08-21
RU2588650C2 (ru) 2016-07-10
JP6310440B2 (ja) 2018-04-11
CA2776790A1 (en) 2011-04-14
AU2010304922A1 (en) 2012-03-29
EP3611185A1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
KR102213154B1 (ko) 재조합 ｈｃｇ를 포함하는 약학 조제물
KR102108377B1 (ko) α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
JP2017101030A (ja) 医薬製剤
HK40020346A (en) Pharmaceutical preparation
HK1174338B (en) Pharmaceutical preparation comprising recombinant hcg
HK1174338A (en) Pharmaceutical preparation comprising recombinant hcg

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190604

Application number text: 1020197007226

Filing date: 20190312

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190604

Comment text: Request for Examination of Application

AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190808

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191205

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200723

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191205

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20190808

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200723

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191008

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190612

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190604

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20201101

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20201020

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200723

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191008

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190612

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190604

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210201

Application number text: 1020197007226

Filing date: 20190312

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210201

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240129

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250121

Start annual number: 5

End annual number: 5